The United Laboratories International Holdings Limited (TUL) is a Hong Kong–listed pharmaceutical group engaged in the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs), intermediates, and finished dosage formulations. Its operations are primarily based in mainland China with a vertically integrated model that spans fermentation, synthesis, and formulation.
TUL is known for large-scale production of beta-lactam antibiotics, including penicillin and cephalosporin series, alongside a portfolio of generic medicines covering anti-infective, cardiovascular, metabolic, and other common therapeutic areas. The company supplies hospitals, pharmacies, and industrial customers in China and exports selected APIs to international markets under applicable quality and GMP standards.
Triple-agonist UBT251 (GLP-1/GIP/glucagon) induced up to 9.8% weight loss, improved BP and lipids vs placebo/semaglutide. Safety consistent with triple-G class; global phase-2 and China phase-3 planned
UBT251, a triple agonist, showed significant weight loss and improved health markers in a Chinese phase 2 trial, with a safe and well-tolerated profile.
